Chimerix to Present at Cowen and Company 2nd Annual Virtual Oncology Innovation Summit
May 13, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update
May 06, 2021 07:00 ET
|
Chimerix, Inc.
– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 – – DSTAT COVID 19 Trial Advances to Cohort 3 at Higher Dose – – Conference Call at 8:30...
Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021
April 29, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Appoints Vicki Vakiener to Board of Directors
April 26, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 08, 2021 16:01 ET
|
Chimerix, Inc.
DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
March 02, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Promising Topline Results from First Cohort of a Randomized COVID-19 Trial with DSTAT
February 25, 2021 07:00 ET
|
Chimerix, Inc.
– Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to...
Chimerix Reports Fourth Quarter and Year End 2020 Financial Results and Provides Operational Update
February 25, 2021 07:00 ET
|
Chimerix, Inc.
– Acquisition of Oncoceutics Adds Late-Stage Precision Oncology Pipeline – – Recently Completed Financing Supports Broad Investment Across Pipeline – – Conference Call at 8:30 a.m....
Chimerix to Report Fourth Quarter and Year End 2020 Financial Results and Provide an Operational Update on February 25, 2021
February 18, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
January 25, 2021 17:44 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...